ABBV Trading Analysis - 10/23/2026 01:18 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• AbbVie's recent ex-dividend date of October 15, 2026 passed with a $6.92 annual dividend rate, a routine catalyst that may have supported income-focused demand.
• Pipeline updates on immunology drugs Skyrizi and Rinvoq through Q3 2026 boosted long-term growth narrative despite looming Humira loss-of-exclusivity concerns.
• Broad pharma sector stabilized in October 2026 amid lower rate-cut expectations, reducing beta-sensitive volatility for low-beta names like ABBV.
• No major earnings catalyst before the next major option expiration (2026-11-20); fiscal year end was December 2025 per fundamentals.
• Context: Headlines reflect defensive, income-oriented interest which aligns with the bullish options flow but not with overbought RSI from embedded data.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data (FinWin local source, retrieved 2026-10-23):

• Trailing P/E is 81.20 and trailing EPS is $3.56; no forward P/E, PEG, or profit margin data supplied.
• Dividend yield 2.39% with rate $6.92, ex-dividend 2026-10-15; market cap $502.52B, shares out 1.77B.
• Beta 0.11 (very low market sensitivity); 52-week range $190.75 to $291.40; current price near 52-week high.
• Institutional ownership 52.91%; average volume 5.06M; historical volatility 18.78%.
• Missing fields: revenue growth, ROE, debt/equity, FCF, analyst target, recommendation key (all null).
• Alignment: High valuation (P/E 81.20) and low beta contrast with strong momentum and bullish options sentiment; fundamentals alone show no earnings trend, creating divergence from technical strength.

Current Market Position

Current price per indicators: $284.37 (2026-10-22 close). Daily history shows 30-day high $291.40 (2026-10-15) and low $253.92 (2026-09-11). Last 5 daily closes: 10-20 $287.91, 10-21 $284.39, 10-22 $284.37 with intraday low $278.01.

Minute bars (2026-10-21 to 10-22): Open 10-21 $287.63, faded to close 10-22 $284.57; last bars show volume spike to 379,569 at 15:55. Intraday momentum negative late session but stabilized near $284.44–$284.57.

Technical Analysis

• SMA alignment: Price > SMA5 > SMA20 > SMA50; bullish stack, no bearish cross.
• RSI 74.19 indicates overbought; momentum stretched but not reversing.
• MACD 6.47 above signal 5.18, histogram +1.29 = bullish continuation.
• Bollinger: Price $284.37 between mid $273.98 and upper $292.29; upper band acts as resistance.
• 30-day range: Price at 88% of range ($253.92–$291.40), near top.

True Sentiment Analysis (Delta 40-60 Options)

From True Sentiment options data (2026-10-23):

Call Volume: $1,785,115 (93.9%) Put Volume: $116,390 (6.1%) Total: $1,901,505

• Sentiment: Bullish (call contracts 857 vs put 67).
• Pure directional conviction strongly favors calls; near-term upside expected by market makers.
• Divergence: Options bullish but spread engine noted "technicals show no clear direction" (overbought RSI vs MACD bullish).

Key Price Levels (Observational Only)